Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT03551522 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03551522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03551522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2018
Completion date
August 10, 2020
Enrollment
181 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis